Investigating how neutrophils contribute to arthritis damage
Official title: Understanding A Molecular Cascade That Drives Neutrophil Mediated Pathology In Arthritis
Funded at University of Virginia · NIH-11019684 · Data updated 2026-11-12
This study is looking at how a type of white blood cell called neutrophils contributes to inflammation and joint damage in rheumatoid arthritis, with the hope of finding new ways to help manage symptoms for people living with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | February 9, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $553,548 |
| NIH project number | 5R01AI158596-03 |
| Project ID | NIH-11019684 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who experience significant inflammation and joint pain.
✕Less likely to help
Patients with other forms of arthritis or those who do not have significant neutrophil involvement in their condition may not benefit from this research.
What this research studies
This research focuses on understanding the role of neutrophils, a type of white blood cell, in the inflammation and joint damage seen in rheumatoid arthritis (RA). By studying the molecular mechanisms that drive neutrophil activity, the researchers aim to identify new therapeutic targets that could help control the symptoms of RA. The study involves using animal models to observe how the absence of a specific protein, ELMO1, affects the severity of arthritis, which could lead to new treatment strategies for patients. If successful, this research could pave the way for more effective therapies that specifically target neutrophil function in arthritis.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce inflammation and joint damage in rheumatoid arthritis patients.
How similar studies have gone: Previous research has shown that targeting neutrophil activity can lead to improvements in inflammatory conditions, suggesting that this approach may be promising.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Arandjelovic, Sanja — University of Virginia
- Study coordinator: Arandjelovic, Sanja
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Dose guide for physical activity to improve arthritis symptoms
A study from the University of South Carolina will look at how different amounts of weekly physical activity affect arthritis symptoms and quality of life in adults with arthritis.
-
Collaborating Center for Arthritis Care Tools and a Coordinating Center for an Arthritis Management & Wellbeing Network
A coordinated NIH program aims to improve how primary care providers refer people with arthritis to evidence-based, self-management programs and to boost participation, especially among groups facing disparities.
-
Arthritis prevention program to help adults with OA in mountain west communities
A program to help adults with osteoarthritis in the Mountain West connect with physical activity counseling and community activities to reduce activity limitations.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.